Technical Analysis for KERX - Keryx Biopharmaceuticals, Inc.
|Grade||Last Price||% Change||Price Change|
KERX closed down 2.04 percent on Wednesday, December 12, 2018, on 2.07 times normal volume. It was able to find support at its 50 day moving average. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
|Weak or Absent||Down||Up||Up|
|See historical KERX trend table...|
|Date||Alert Name||Type||% Chg|
|Dec 12||20 DMA Support||Bullish||0.00%|
|Dec 12||50 DMA Support||Bullish||0.00%|
|Dec 12||Wide Range Bar||Range Expansion||0.00%|
|Dec 12||Upper Bollinger Band Walk||Strength||0.00%|
|Dec 12||Wide Bands||Range Expansion||0.00%|
|Dec 12||Overbought Stochastic||Strength||0.00%|
|Dec 12||Upper Bollinger Band Touch||Strength||0.00%|
|Dec 11||Above Upper BB||Strength||-2.04%|
|Dec 11||Overbought Stochastic||Strength||-2.04%|
|Dec 11||Upper Bollinger Band Touch||Strength||-2.04%|
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of renal disease in the United States. It is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes. The company has completed Phase III clinical program for Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease on dialysis. Zerenex is also in Phase II development for the management of phosphorus and iron deficiency in anemic patients with stages three to five non-dialysis dependent chronic kidney diseases. The company has sublicense agreements with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of Zerenex in Japan. It also has strategic alliances with Panion & BF Biotech, Inc.; Japan Tobacco Inc.; and Torii Pharmaceutical Co., Ltd. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in New York, New York.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more KERX news...
|52 Week High||5.98|
|52 Week Low||2.47|
|200-Day Moving Average||3.9651|
|50-Day Moving Average||3.0344|
|20-Day Moving Average||2.9695|
|10-Day Moving Average||3.155|
|Average True Range||0.2495|
|Chandelier Exit (Long, 3 ATRs )||2.9015|
|Chandelier Exit (Short, 3 ATRs )||3.2185|
|Upper Bollinger Band||3.4307|
|Lower Bollinger Band||2.5083|
|Percent B (%b)||0.92|
|MACD Signal Line||0.0267|
|Market Cap||399 Million|
|Num Shares||119 Million|
|Price-to-Earnings (P/E) Ratio||-1.95|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||4.11|
|Resistance 3 (R3)||4.06||3.76||3.99|
|Resistance 2 (R2)||3.76||3.57||3.79||3.94|
|Resistance 1 (R1)||3.56||3.45||3.41||3.61||3.90|
|Support 1 (S1)||3.06||3.07||2.91||3.11||2.82|
|Support 2 (S2)||2.76||2.95||2.79||2.78|
|Support 3 (S3)||2.56||2.76||2.74|
|Support 4 (S4)||2.61|